Posted by Michael Wonder on 25 Apr 2019
A Commerce Department report causes a stir over whether to use federal law to lower drug prices
24 April 2019 - At the same time the Trump administration has vowed to attack rising drug costs, the Department of Commerce has released a report that some academics and consumer advocates argue would restrain the ability of the federal government to limit “excessive” prescription drug prices.
In a lengthy document that largely mirrors a draft report leased late last year, the department’s National Institute of Standards and Technology offers suggestions for modernising technology transfer and innovation, and proposed several ideas for maximising returns on taxpayer investment in R&D.
